Scientists have announced a new maternal blood test that can detect thousands of serious genetic conditions in a developing fetus, potentially reducing the need for invasive screening methods that involve needles and anxiety. The test, described at the European Society for Human Genetics conference in Gothenburg on Saturday, relies on detecting tiny fragments of fetal DNA circulating in the mother's bloodstream. Using advanced sequencing techniques, researchers identified a very high proportion of genetic conditions - including cystic fibrosis, Noonan syndrome, Charge syndrome, Stickler syndrome, and achondroplasia - that currently require amniocentesis or chorionic villus sampling (CVS) for reliable diagnosis.
The new technique, called non-invasive fetal sequencing (NIFS), could serve as a safer, equally accurate screening tool for all pregnancies, according to Dr. Christopher Whelan, a senior computational scientist at the Broad Institute of MIT and Harvard. “This test is capable of detecting thousands of serious genetic conditions, including the majority of the conditions that appear on major newborn sequencing and fetal anomaly panels, such as the over 2,500-gene Genomics England fetal anomalies panel,” he said. The test was validated on 565 pregnancies at an average of 17 weeks of gestation, sequencing nearly 23,000 genes per fetus. Comparing results to those from amniocentesis or CVS, NIFS picked up 95-99% of genetic variants found by invasive methods and over 97% of clinically relevant variants.
Non-invasive blood tests based on fetal DNA have already revolutionized prenatal diagnostics but were previously limited to a handful of conditions like Down's syndrome. This expansion, if confirmed, would cover nearly all genetic conditions on newborn screening panels. “We envision this as a frontline test for cases where the fetus has presented with an anomaly in an ultrasound or another screening test,” said Whelan, noting that many women currently decline invasive methods due to miscarriage risks - about one in 200 for amniocentesis - stress, access issues, and cost.
Experts are cautiously impressed. Prof. Alexandre Reymond of the University of Lausanne called it “a tour de force” that “immediately opens up treatment and prevention opportunities” and will “change reproductive medicine forever.” Prof. Angus Clarke, a clinical geneticist at Cardiff University, described it as a “very impressive technical feat” useful when a genetic condition is suspected and prenatal treatment is possible. However, he warned that using the test for exploratory screening could turn up genes of unknown significance, causing “huge anxiety” for parents and potentially leading to unnecessary medicalization. “When you don’t have a problem that you’re looking for an answer to, just coming out with potential answers can cause more problems,” he said. So, it's a breakthrough - just maybe don't go looking for problems you didn't know you had.